RAC 3.31% $1.61 race oncology ltd

Ann: Zantrene Improves Immune Therapy Treatment of Melanoma, page-84

  1. 2,704 Posts.
    lightbulb Created with Sketch. 2823
    Interesting!

    So in short, T-cell therapies are being used to turn ‘cold’ tumours ‘hot’ where CPI do not.

    Good thing there is strong correlation between CD8+ levels and FTO expression. Thus Inhibiting FTO might yield similar benefits albeit via a different pathway.

    At the end of the day, if the tap can be turned from cold to hot, doesn’t matter how it was done!
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.